Trial Profile
An open, multicenter phase II trial evaluating the antitumour efficacy of Faslodex (fulvestrant) in postmenopausal women with advanced breast cancer failing non-steroidal or steroidal aromatase inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer; Menopause
- Focus Therapeutic Use
- Acronyms SAKK
- Sponsors AstraZeneca
- 27 Mar 2007 New trial record.